Advertisement

Current State of Platinum Complexes for the Treatment of Advanced and Drug-Resistant Breast Cancers

  • Bernhard Biersack
  • Rainer Schobert
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1152)

Abstract

Breast cancer represents the major cause of death in female cancer patients. New efficient treatments are desperately needed, particularly especially for patients suffering from advanced stages and metastases, or those who are no longer responding to the clinically established drugs such as cisplatin or carboplatin. New promising therapy regimens and platinum complexes have emerged over the last few years that displayed efficacy in advanced platinum- and/or drug-resistant breast tumors and metastases. This chapter provides an overview of the latest developments in the field of platinum-based drugs against advanced and resistant breast cancers since 2013.

Keywords

Platinum complexes Anticancer agents Breast cancer Metastasis Multidrug resistance (MDR) Triple-negative breast cancer (TNBC) 

Notes

Acknowledgments

Own work referenced in this chapter was supported by grants from the Deutsche Forschungsgemeinschaft (Scho 402/8 and Scho 402/12).

References

  1. 1.
    Rosenberg B, VanCamp L, Trosko JE, Mansour VH (1969) Platinum compounds: a new class of potent antitumour agents. Nature 222:385–386PubMedCrossRefGoogle Scholar
  2. 2.
    Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99:2467–2498CrossRefGoogle Scholar
  3. 3.
    Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307–320CrossRefGoogle Scholar
  4. 4.
    Kartalou M, Essigmann JM (2001) Mechanisms of resistance to cisplatin. Mutat Res Fundam Mol Mech Mutagen 478:23–43CrossRefGoogle Scholar
  5. 5.
    Oh GS, Kim HJ, Shen A, Lee SB, Khadka D, Pandit A, So HS (2014) Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies. Electrolyte Blood Pressure 12:55–65PubMedCrossRefGoogle Scholar
  6. 6.
    Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364–378CrossRefGoogle Scholar
  7. 7.
    Schobert R, Biersack B, Dietrich A, Grotemeier A, Müller T, Kalinowski B, Knauer S, Voigt W, Paschke R (2007) Monoterpenes as drug shuttles: cytotoxic (6-aminomethylnicotinate) dichloridoplatinum(II) complexes with potential to overcome cisplatin resistance. J Med Chem 50:1288–1293PubMedCrossRefGoogle Scholar
  8. 8.
    Zoldakova M, Biersack B, Kostrhunova K, Ahmad A, Padhye S, Sarkar FH, Schobert R, Brabec V (2011) (Carboxydiamine)Pt(II) complexes of a combretastatin A-4 analogous chalcone: the influence of the diamine ligand on DNA binding and anticancer effects. Med Chem Commun 2:493–499CrossRefGoogle Scholar
  9. 9.
    Najajreh Y, Perez JM, Navarro-Ranninger C, Gibson D (2002) Novel soluble cationic trans-diaminedichloroplatinum(II) complexes that are active against cisplatin resistant ovarian cancer cell lines. J Med Chem 45:5189–5195PubMedCrossRefGoogle Scholar
  10. 10.
    Liu W, Gust R (2013) Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs. Chem Soc Rev 42:755–773PubMedCrossRefGoogle Scholar
  11. 11.
    Ferlay J, Soerjomataram I, Dikshit R, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386CrossRefGoogle Scholar
  12. 12.
    DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A (2016) Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin 66:31–42PubMedCrossRefGoogle Scholar
  13. 13.
    Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S (2014) The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systemic review and meta-analysis. Breast Cancer Res Treat 144:223–232PubMedCrossRefGoogle Scholar
  14. 14.
    Chen X, Lu P, Wu Y, Wang D, Zhou S, Yang S, Shen H, Zhang X, Zhao J, Tang T (2016) MiRNAs-mediated cisplatin resistance in breast cancer. Tumor Biol 37:12905–12913CrossRefGoogle Scholar
  15. 15.
    Biersack B (2017) Interactions between anticancer active platinum complexes and non-coding RNAs/microRNAs. Non-Coding RNA Res 2:1–17CrossRefGoogle Scholar
  16. 16.
    Biersack B, Schobert R (2013) Platinum and ruthenium complexes for the therapy of breast cancer diseases. In: Ahmad A (ed) Breast cancer metastasis and drug resistance. Springer Science+Business Media, New YorkGoogle Scholar
  17. 17.
    Cobleigh MA (2011) Other options in the treatment of advanced breast cancer. Semin Oncol Suppl 2:S11–S16CrossRefGoogle Scholar
  18. 18.
    Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winter EP, Weeks JC (2012) Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the national comprehensive cancer network. Cancer 118:5463–5472PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman A-R, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW (2015) TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 33:1902–1909PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman A-R, Garber JE, Ford JM, Silver DP, Richardson AL (2016) Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 22:3764–3773PubMedCrossRefGoogle Scholar
  21. 21.
    Ratner ES, Zhu Y-L, Penketh PG, Berenblum J, Whicker ME, Huang PH, Lee Y, Ishiguro K, Zhu R, Sartorelli AC, Lin ZP (2016) Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair. Br J Cancer 114:777–786PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Hu X-C, Zhang J, Xu B-H, Cai L, Ragaz J, Wang Z-H, Wang B-Y, Teng Y-E, Tong Z-S, Pan Y-Y, Yin Y-M, Wu C-P, Jiang Z-F, Wang X-J, Lou G-Y, Liu D-G, Feng J-F, Luo J-F, Sun K, Gu Y-J, Wu J, Shao Z-M (2015) Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomized, open-label, multicenter, phase 3 trial. Lancet Oncol 16:436–446PubMedCrossRefGoogle Scholar
  23. 23.
    Habbel P, Kurreck A, Schulz C-O, Regierer AC, Kaul D, Scholz CW, Neumann C, Possinger K, Eucker J (2015) Cisplatin plus ifosfamide with/without etoposide as salvage therapy in heavily-pre-treated patients with metastatic breast cancer. Anticancer Res 35:5091–5096PubMedGoogle Scholar
  24. 24.
    Ibrahim T, Liverani C, Mercatali L, Sacanna E, Zanoni M, Fabbri F, Zoli W, Amadori D (2013) Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines. Int J Oncol 42:1263–1270PubMedCrossRefGoogle Scholar
  25. 25.
    Singh JC, Novik Y, Stein S, Volm M, Meyers M, Smith J, Omene C, Speyer J, Schneider R, Jhaveri K, Formenti S, Kyriakou V, Joseph B, Goldberg JD, Li X, Adams S, Tiersten A (2014) Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res 16:R32PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Karginova O, Siegel MB, Van Swearingen AED, Deal AM, Adamo B, Sambade MJ, Bazyar S, Nikolaishvili-Feinberg N, Bash R, O’Neal S, Sandison K, Parker JS, Santos C, Darr D, Zamboni W, Lee YZ, Miller CR, Anders CK (2015) Efficacy of carboplatin alone or in combination with ABT888 in intracranial murine models of BRCA-mutated and BRCA-wild-type triple-negative breast cancer. Mol Cancer 14:920–930CrossRefGoogle Scholar
  27. 27.
    Pang H, Feng T, Lu H, Meng Q, Chen X, Shen Q, Dong X, Cai L (2016) Efficacy and safety of nedaplatin in advanced breast cancer therapy. Cancer Investig 34:167–172CrossRefGoogle Scholar
  28. 28.
    Zhang J, Wang L, Wang Z, Hu X, Wang B, Cao J, Lv F, Zhen C, Zhang S, Shao Z (2015) A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer. Cancer Biol Ther 16:225–232PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Varela JG, Chatterjee AD, Guevara P, Ramirez V, Metta-Magana AJ, Villagrán D, Varela-Ramirez A, Das S, Nunez JE (2014) Synthesis, characterization, and evaluation of cis-diphenyl pyridineamine platinum(II) complexes as potential anti-breast cancer agents. J Biol Inorg Chem 19:967–979PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Tomé M, López C, González A, Ozay B, Quirante J, Font-Bardía M, Calvet T, Calvis C, Messeguer R, Baldomá L, Badía J (2013) Trans- and cis-2-phenylindole platinum(II) complexes as cytotoxic agents against human breast adenocarcinoma cell lines. J Mol Struct 1048:88–97CrossRefGoogle Scholar
  31. 31.
    Zhang H, Gou S, Zhao J, Chen F, Xu G, Liu X (2015) Cytotoxicity profile of novel sterically hindered platinum(II) complexes with (1R,2R)-N1,N2-dibutyl-1,2-diaminocyclohexane. Eur J Med Chem 96:187–195PubMedCrossRefGoogle Scholar
  32. 32.
    Peng Y, Zhong H, Chen Z-F, Liu Y-C, Zhang G-H, Qin Q-P, Liang H (2014) A planar Schiff base platinum(II) complex: crystal structure, cytotoxicity and interaction with DNA. Chem Pharm Bull 62:221–228PubMedCrossRefGoogle Scholar
  33. 33.
    Jean S, Cormier K, Patterson AE, Vogels CM, Decken A, Robichaud GA, Turcotte S, Westcott SA (2015) Synthesis, characterization, and anticancer properties of organometallic Schiff base platinum complexes. Can J Chem 93:1140–1146CrossRefGoogle Scholar
  34. 34.
    Savic A, Filipovic L, Arandelovic S, Dojcinovic B, Radulovic S, Sabo TJ, Grguric-Sipka S (2014) Synthesis, characterization and cytotoxic activity of novel platinum(II) iodide complexes. Eur J Med Chem 82:372–384PubMedCrossRefGoogle Scholar
  35. 35.
    Utku S, Ozcelik AB, Gümüs F, Yilmaz S, Arsoy T, Acik L, Keskin AC (2014) Synthesis, in-vitro cytotoxic activity and DNA interactions of new dicarboxylatoplatinum(II) complexes with 2-hydroxymethylbenzimidazole as carrier ligands. J Pharm Pharmacol 66:1593–1605PubMedCrossRefGoogle Scholar
  36. 36.
    Albert J, D’Andrea L, Granell J, Pla-Vilanova P, Quirante J, Khosa MK, Calvis C, Messeguer R, Badía J, Baldomà L, Font-Bardia M, Calvet T (2014) Cyclopalladated and cycloplatinated benzophenone imines: antitumor, antibacterial and antioxidant activities, DNA interaction and cathepsin B inhibition. J Inorg Biochem 140:80–88PubMedCrossRefGoogle Scholar
  37. 37.
    Talancón D, López C, Font-Bardía M, Calvet T, Quirante J, Calvis C, Messeguer R, Cortés R, Cascante M, Baldomà L, Badia H (2013) Diastereomerically pure platinum(II) complexes as antitumoral agents. The influence of the mode of binding {(N), (N,O) or (C,N)} of (1S,2R)-[(η5 –C5H5)Fe{(η5 –C5H4)-CH=N-CH(Me)-CH(OH)-C6H5}] and the arrangement of the auxiliary ligands. J Inorg Biochem 118:1–12PubMedCrossRefGoogle Scholar
  38. 38.
    El-Asmy HA, Butler IS, Mouhri ZS, Jean-Claude BJ, Emmam MS, Mostafa SI (2014) Zinc(II), ruthenium(II), rhodium(III), palladium(II), silver(I), platinum(II) and MoO22+ complexes of 2-(2′-hydroxy-5′-methylphenyl)-benzotriazole as simple or primary ligand and 2,2′-bipyridyl, 9,10-phenanthroline or triphenylphosphine as secondary ligands: structure and anticancer activity. J Mol Struct 1059:193–201CrossRefGoogle Scholar
  39. 39.
    Villareal W, Colina-Vegas L, de Oliveira CR, Tenorio JC, Ellena J, Gozzo FC, Cominetti MR, Ferreira AG, Ferreira MAB, Navarro M, Batista AA (2015) Chiral platinum(II) complexes featuring phosphine and chloroquine ligands as cytotoxic and monofunctional DNA-binding agents. Inorg Chem 54:11709–11720CrossRefGoogle Scholar
  40. 40.
    Tsai JL-L, Zou T, Liu J, Chen T, Chan AO-Y, Yang C, Lok C-N, Che C-M (2015) Luminescent platinum(II) complexes with self-assembly and anti-cancer properties: hydrogel, pH dependent emission color and sustained-release properties under physiological conditions. Chem Sci 6:3823–3830PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Czapar AE, Zheng Y-R, Riddell IA, Shukla S, Awuah SG, Lippard SJ, Steinmetz NF (2016) Tobacco mosaic virus delivery of phenanthriplatin for cancer therapy. ACS Nano 10:4119–4126PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Fahrenholtz CD, Ding S, Bernish BW, Wright ML, Zheng Y, Yang M, Yao X, Donati GL, Gross MD, Bierbach U, Singh R (2016) Design and cellular studies of a carbon nanotube-based delivery system for a hybrid platinum-acridine anticancer agent. J Inorg Biochem 165:170–180PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Dag A, Callari M, Lu H, Stenzel MH (2016) Modulating the cellular uptake of platinum drugs with glycopolymers. Polym Chem 7:1031–1036CrossRefGoogle Scholar
  44. 44.
    Apps MG, Ammit AJ, Gu A, Wheate NJ (2014) Analysis of montmorillonite clay as a vehicle in platinum anticancer drug delivery. Inorg Chim Acta 421:513–518CrossRefGoogle Scholar
  45. 45.
    Gegotek A, Cyunczyk M, Luczaj W, Bielawska A, Bielawski K, Skrzydlewska E (2014) The redox status of human breast cancer cell lines (MCF-7 and MDA-MB231) treated with novel dinuclear berenil-platinum(II) complexes. Pharmazie 69:923–928PubMedGoogle Scholar
  46. 46.
    Bielawski K, Czarnomysy R, Muszynska A, Bielawska A, Poplawska B (2013) Cytotoxicity and induction of apoptosis of human breast cancer cells by novel platinum(II) complexes. Environ Toxicol Pharmacol 35:254–264PubMedCrossRefGoogle Scholar
  47. 47.
    Gornowicz A, Kaluza Z, Bielawska A, Gabryel-Porowska H, Czarnomysy R, Bielawski K (2014) Cytotoxic efficacy of a novel dinuclear platinum(II) complex used with anti-MUC1 in human breast cancer cells. Mol Cell Biochem 392:161–174PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Gornowicz A, Bielawska A, Czarnomysy R, Gabryel-Porowska H, Muszynska A, Bielawski K (2015) The combined treatment with novel platinum(II) complex and anti-MUC1 increases apoptotic response in MDA-MB-231 breast cancer cells. Mol Cell Biochem 408:103–113PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Czarnomysy R, Bielawski K, Muszynska A, Bielawska A, Gornowicz A (2016) Biological evaluation of dimethylpyridine-platinum complexes with potent antiproliferative activity. J Enzyme Inhib Med Chem 31:150–165PubMedCrossRefGoogle Scholar
  50. 50.
    Shahin M, Safaei-Nikouei N, Lavasanifar A (2014) Polymeric micelles for pH-responsive delivery of cisplatin. J Drug Target 22:629–637PubMedCrossRefGoogle Scholar
  51. 51.
    Voigt W, Dietrich A, Schmoll H-J (2006) Cisplatin und seine Analoga. Pharm Unserer Zeit 35:134–143PubMedCrossRefGoogle Scholar
  52. 52.
    Smith JW III, McIntyre KJ, Avecedo PV, Encarnacion CA, Tedesco KL, Wang Y, Asmar L, O’Shaughnessy (2009) Results of a phase II open-label, non-randomized trial of oral satraplatin in patients with metastatic breast cancer. Breast Cancer Res Treat 118:361–367PubMedCrossRefGoogle Scholar
  53. 53.
    Wilson JJ, Lippard SJ (2014) Synthetic methods for the preparation of platinum anticancer complexes. Chem Rev 114:4470–4495PubMedCrossRefGoogle Scholar
  54. 54.
    Neumann W, Crews BC, Sárosi MB, Daniel CM, Ghebreselasie K, Scholz MS, Marnett LJ, Hey-Hawkins E (2015) Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance. Chem Med Chem 10:183–192PubMedCrossRefGoogle Scholar
  55. 55.
    Giglio V, Oliveri V, Viale M, Gangemi R, Natile G, Intini FP, Vecchio G (2015) Folate-cyclodextrin conjugates as carriers of the platinum(IV) complex LA-12. Chem Plus Chem 80:536–543Google Scholar
  56. 56.
    Wong DYQ, Yeo CHF, Ang WH (2014) Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer agents. Angew Chem Int Ed 53:6752–6756CrossRefGoogle Scholar
  57. 57.
    Yuan Y, Chen Y, Tang BZ, Liu B (2014) A targeted theranostic platinum(IV) prodrug containing a luminogen with aggregation-induced emission (AIE) characteristics for in situ monitoring of drug activation. Chem Commun 50:3868–3870CrossRefGoogle Scholar
  58. 58.
    Yuan Y, Zhang C-J, Liu B (2015) A platinum prodrug conjugated with a photosensitizer with aggregation-induced emission (AIE) characteristics for drug activation monitoring and combinatorial photodynamic-chemotherapy against cisplatin resistant cancer cells. Chem Commun 51:8626–8629CrossRefGoogle Scholar
  59. 59.
    Shi H, Cheng Q, Yuan S, Ding X, Liu Y (2015) Human serum albumin conjugated nanoparticles for pH and redox-responsive delivery of a prodrug of cisplatin. Chem Eur J 21:16547–16554PubMedCrossRefGoogle Scholar
  60. 60.
    Lozano-Pérez AA, Gil AL, Pérez SA, Cutillas N, Meyer H, Pedreno M, Aznar-Cervantes SD, Janiak C, Cenis JL, Ruiz J (2015) Antitumor properties of platinum(IV) prodrug-loaded silk fibroin nanoparticles. Dalton Trans 44:13513–13521PubMedCrossRefGoogle Scholar
  61. 61.
    Johnstone TC, Kulak N, Pridgen EM, Farokhzad OC, Langer R, Lippard SJ (2013) Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties. ACS Nano 7:5675–5683PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Ang WH, Khalaila I, Allardyce CS, Juillerat-Jeanneret L, Dyson PJ (2005) Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. J Am Chem Soc 127:1382–1383PubMedCrossRefGoogle Scholar
  63. 63.
    LaPensee EW, Schwemberger SJ, LaPensee CR, Bahassi EM, Afton SE, Ben-Jonathan N (2009) Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase. Carcinogenesis 30:1298–1304PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Hoffmann K, Lakomska I, Wisniewska J, Kaczmarek-Kedziera A, Wietrzyk J (2015) Acetate platinum(II) compound with 5,7-ditertbutyl-1,2,4-triazolo[1,5-a]pyrimidine that overcomes cisplatin resistance: structural characterization, in vitro cytotoxicity, and kinetic studies. J Coord Chem 68:3193–3208CrossRefGoogle Scholar
  65. 65.
    Lakomska I, Hoffmann K, Wojtczak A, Sitkowski J, Maj E, Wietrzyk J (2014) Cytotoxic malonate platinum(II) complexes with 1,2,4-triazolo[1,5-a]pyrimidine derivatives: structural characterization and mechanism of the suppression of tumor cell growth. J Inorg Biochem 141:188–197PubMedCrossRefGoogle Scholar
  66. 66.
    Zamora A, Rodríguez V, Cutillas N, Yellol GS, Espinosa A, Samper K, Capdevila M, Palacios O, Ruiz J (2013) New steroidal 7-azaindole platinum(II) antitumor complexes. J Inorg Biochem 128:48–56PubMedCrossRefGoogle Scholar
  67. 67.
    Cutillas N, Mart’nez A, Yellol GS, Rodríguez V, Zamora A, Pedreno M, Donaire A, Janiak C, Ruiz J (2013) Anticancer C,N-cycloplatinated(II) complexes containing fluorinated phosphine ligands: synthesis, structural characterization, and biological activity. Inorg Chem 52:13529–13535PubMedCrossRefGoogle Scholar
  68. 68.
    Nieto D, Bruna S, González-Vadillo AM, Perles J, Carillo-Hermosilla F, Antinolo A, Padrón JM, Plata GB, Cuadrado I (2015) Catalytically generated ferrocene-containing guanidines as efficient precursors for new redox-active heterometallic platinum(II) complexes with anticancer activity. Organometallics 34:5407–5417CrossRefGoogle Scholar
  69. 69.
    Huang R, Wang Q, Zhang X, Zhu J, Sun B (2015) Trastuzumab-cisplatin conjugates for targeted delivery of cisplatin to HER2-overexpressing cancer cells. Biomed Pharmacother 72:17–23PubMedCrossRefGoogle Scholar
  70. 70.
    Huang R, Sun Y, Zhang X, Sun B, Wang Q, Zhu J (2015) Biological evaluation of a novel Herceptin-platinum(II) conjugate for efficient and cancer cell specific delivery. Biomed Pharmacother 73:116–122PubMedCrossRefGoogle Scholar
  71. 71.
    Alavizadeh SH, Akhtari J, Badiee A, Golmohammadzadeh S, Jaafari MR (2015) Improved therapeutic activity of HER2 affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models. Exp Opin Drug Deliv 13:325–336CrossRefGoogle Scholar
  72. 72.
    Muscella A, Vetrugno C, Fanizzi FP, Manca C, De Pascali SA, Marsigliante S (2013) A new platinum(II) compound anticancer drug candidate with selective cytotoxicity for breast cancer cells. Cell Death Dis 4:e796PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Karmakar S, Chatterjee S, Purkait K, Mukherjee A (2016) Anticancer activity of a chelating nitrogen mustard bearing tetrachloroplatinum(IV) complex: better stability yet equipotent to the Pt(II) analogue. Dalton Trans 45:11710–11722PubMedCrossRefGoogle Scholar
  74. 74.
    Liu W, Ye Q, Jiang J, Lou L, Xu Y, Xie C, Xie M (2013) cis-[PtII(1R,2R-DACH)(3-acetoxy-1,1-cyclobutanedicarboxylato)], a water-soluble, oxalate-free and stable analogue of oxaliplatin: synthesis, characterization, and biological evaluations. Chem Med Chem 8:1465–1467PubMedCrossRefGoogle Scholar
  75. 75.
    Muenzner JK, Rehm T, Biersack B, Casini A, de Graaf IAM, Worawutputtapong P, Noor A, Kempe R, Brabec V, Kasparkova J, Schobert R (2015) Adjusting the DNA interaction and anticancer activity of Pt(II) N-heterocyclic carbene complexes by steric shielding of the trans leaving group. J Med Chem 58:6283–6292PubMedCrossRefGoogle Scholar
  76. 76.
    Rehm T, Rothemund M, Muenzner JK, Noor A, Kempe R, Schobert R (2016) Novel cis-[(NHC)1(NHC)2(L)Cl]platinum(II) complexes – synthesis, structures, and anticancer activities. Dalton Trans 45:15390–15398PubMedCrossRefGoogle Scholar
  77. 77.
    Schmitt F, Donnelly K, Muenzner JK, Rehm T, Novohradsky V, Brabec V, Kasparkova J, Albrecht M, Schobert R, Mueller T (2016) Effects of histidine-2-ylidene vs. imidazole-2-ylidene ligands on the anticancer and antivascular activity of complexes of ruthenium, iridium, platinum, and gold. J Inorg Biochem 163:221–228PubMedCrossRefGoogle Scholar
  78. 78.
    Liu H, Li Y, Lyu Z, Wan Y, Li X, Chen H, Chen H, Li X (2014) Enzyme-triggered supramolecular self-assembly of platinum prodrug with enhanced tumor-selective accumulation and reduced systemic toxicity. J Mater Chem B 2:83038309Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Bernhard Biersack
    • 1
  • Rainer Schobert
    • 1
  1. 1.Organic Chemistry LaboratoryBayreuthGermany

Personalised recommendations